Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD
Document Type
Article
Publication Date
2-1-2026
Abstract
Background & Aims Fibrosis-4 Index (FIB-4) is a noninvasive tool for assessing liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). However, its role of dynamic FIB-4 for assessing fibrosis progression and predicting clinical outcomes remains unclear. The aim of this study was to examine the association between changes in FIB-4 and changes in liver stiffness, fibrosis progression, and outcomes in MASLD. Methods Three cohorts were analyzed: VCTE-Prognosis cohort (n = 10,203) for stiffness progression, Paired Liver Biopsy cohort (n = 1,145) for fibrosis progression, and Wenzhou Real-World (WRW) cohort (n = 41,105) for clinical outcomes. Stiffness progression was defined as an increase in liver stiffness measurement, and fibrosis progression by a 1-stage increase. Outcomes included all-cause mortality, cardiovascular events, and liver-related events (LREs). FIB-4 was dichotomized into low (< 1.3) and high (≥1.3). Increases were defined as ≥20% rise and to ≥1.3 in the low FIB-4 group, and ≥20% rise in the high FIB-4 group. Results In the VCTE-Prognosis cohort, stiffness progression was more likely with increasing vs stable FIB-4 (adjusted odds ratio [OR], 2.36; P < .001) in those with low baseline FIB-4. In the high FIB-4 group, stiffness progression rates increased from stable to increasing FIB-4 (adjusted OR, 3.42; P < .001). In the Paired Liver Biopsy cohort, fibrosis progression was more frequent with increasing FIB-4 (adjusted OR, 2.20; P = .004 in low FIB-4; adjusted OR, 3.68; P < .001 in high FIB-4). In the WRW cohort, an increase in dynamic FIB-4 was linked to higher risks for all-cause mortality, cardiovascular events, and LREs (all P < .001). Conclusions Dynamic FIB-4 monitoring tracks fibrosis and stiffness progression and predicts clinical outcomes in MASLD.
Keywords
Fibrosis, Fibrosis-4 Index, Liver Cirrhosis, Metabolic Dysfunction-associated Steatotic Liver Disease, Prognosis
Publication Title
Clinical Gastroenterology and Hepatology
ISSN
1542-3565
DOI
10.1016/j.cgh.2025.07.011
Recommended Citation
Zhou, Xiao Dong; Li, Yu Ting; Kim, Seung Up; Yip, Terry Cheuk Fung; Petta, Salvatore; Nakajima, Atsushi; Tsochatzis, Emmanuel; Shi, Junping; Chan, Wah Kheong; Boursier, Jérôme; Bugianesi, Elisabetta; Yilmaz, Yusuf; Hagström, Hannes; Romero-Gomez, Manuel; Alswat, Khalid; Calleja, José Luis; Takahashi, Hirokazu; and de Lédinghen, Victor, "Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD" (2026). Research Publications (2026 to 2030). 1418.
https://knova.um.edu.my/research_publications_2026_2030/1418
Funders
National Key R&D Program of China, National Natural Science Foundation of China, National Key Research and Development Program of China (2023YFA1800801, 2023ZD0508700), National Natural Science Foundation of China (82070588, 82370577)
Volume
24
Issue
2
First Page
394
Last Page
406
Publisher
W.B. Saunders